<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250811066814N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-09-14</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Laser in Dentisry</public_title>
      <acronym></acronym>
      <scientific_title>Title : Evaluation of the effect of photodynamic therapy on coated orthodontic mini-screws with zinc oxide nanoparticles stability, peri-miniscrew gingival condition and patient pain belief: A parallel randomized controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/85453</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization with a block size of 6 and an individual unit of randomization is used. In each block, all interventions are repeated once. The allocation sequence is generated using a six-sided dice by the study epidemiologist. Randomization is non-stratified. For allocation concealment, the final sequence is placed in opaque, sealed, and numbered envelopes, which are opened only at the time of each participant’s enrollment. Only the study epidemiologist is aware of the allocation sequence and is not involved in intervention delivery or data collection, Blinding description: Only the operator is aware of the allocation. Participants, sample collectors, outcome assessors, and the statistician are blinded to group assignment. All miniscrews (American Orthodontics, USA) are identical in size, shape, and color, and differences related to ZnO coating or LED irradiation are not distinguishable to participants. Therefore, participant-level blinding is feasible. To prevent unblinding during analysis, statistical codes are designed independently from envelope numbers.</study_design>
      <phase>3</phase>
      <hc_freetext>stability of coated orthodontic mini-screws with zinc oxide nanoparticles , peri-miniscrew gingival condition and patient pain belief.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1 (Photodynamic therapy): Titanium miniscrew, 1.6 mm diameter and 10 mm length (American Orthodontics, Sheboygan, WI, USA), coated with zinc oxide nanoparticles (ZnO; Pishgaman Nanomavad Iranian, Mashhad, Iran) using electrostatic spray deposition. After placement, LED irradiation at 450±5 nm and 1000–1400 mW/cm² will be applied for 1 min, repeated once more after force loading. Intervention 2: Intervention group 2 (ZnO): Titanium miniscrew, 1.6 mm diameter and 10 mm length (American Orthodontics, Sheboygan, WI, USA), coated with zinc oxide nanoparticles (ZnO; Pishgaman Nanomavad Iranian, Mashhad, Iran) using electrostatic spray deposition. No LED irradiation will be applied in this group. Intervention 3: Intervention group 3 (LED): Titanium miniscrew, 1.6 mm diameter and 10 mm length (American Orthodontics, Sheboygan, WI, USA), uncoated. After placement, LED irradiation at 450±5 nm and 1000–1400 mW/cm² will be applied for 1 min, repeated once more after force loading. Intervention 4: Intervention group 4 (Positive control): Titanium miniscrew, 1.6 mm diameter and 10 mm length (American Orthodontics, Sheboygan, WI, USA), uncoated and non-irradiated. Patients will use 0.2% chlorhexidine mouthwash (Nazhou, Iran), twice daily for 30 seconds according to manufacturer’s instructions. Intervention 5: Intervention group 5 (Negative control): Titanium miniscrew, 1.6 mm diameter and 10 mm length (American Orthodontics, Sheboygan, WI, USA), uncoated and non-irradiated, without any adjunctive treatment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Rashin Bahrami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadi Street - South Jamalzadeh _ Corner of Jamshid Alley _ No. 168</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1313883851</zip>
        <telephone>+98 21 6691 5656</telephone>
        <email>bahramirashin@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Rashin Bahrami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadi Street - South Jamalzadeh _ Corner of Jamshid Alley _ No. 168</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1313883851</zip>
        <telephone>+98 21 6691 5656</telephone>
        <email>bahramirashin@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients aged 18 to 28 who are periodontally healthy.
Require the use of mini-screws for orthodontic treatment. The orthodontic treatment plan for these patients (diagnosed with Class II Division I malocclusion) involves extraction of the maxillary first premolars and requires absolute anchorage.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>28 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Active gag reflex, smoking, presence of periodontal disease, additional forces including mechanical forces from orthodontics and traumatic occlusion, systemic diseases that interfere with tissue healing such as diabetes, treatment with high-dose steroids, radiotherapy, or immunosuppressive therapies, pregnancy, breastfeeding, gastrointestinal problems, and allergy to impression materials.
Patients who do not attend regular follow-up visits after mini-screw placement.
History of medication use that interferes with healing or causes gingival overgrowth.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>-</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>-</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1 (Photodynamic therapy): Titanium miniscrew, 1.6 mm diameter and 10 mm length (American Orthodontics, Sheboygan, WI, USA), coated with zinc oxide nanoparticles (ZnO; Pishgaman Nanomavad Iranian, Mashhad, Iran) using electrostatic spray deposition. After placement, LED irradiation at 450±5 nm and 1000–1400 mW/cm² will be applied for 1 min, repeated once more after force loading.</i_keyword>
      <i_keyword>Intervention group 2 (ZnO): Titanium miniscrew, 1.6 mm diameter and 10 mm length (American Orthodontics, Sheboygan, WI, USA), coated with zinc oxide nanoparticles (ZnO; Pishgaman Nanomavad Iranian, Mashhad, Iran) using electrostatic spray deposition. No LED irradiation will be applied in this group.</i_keyword>
      <i_keyword>Intervention group 3 (LED): Titanium miniscrew, 1.6 mm diameter and 10 mm length (American Orthodontics, Sheboygan, WI, USA), uncoated. After placement, LED irradiation at 450±5 nm and 1000–1400 mW/cm² will be applied for 1 min, repeated once more after force loading.</i_keyword>
      <i_keyword>Intervention group 4 (Positive control): Titanium miniscrew, 1.6 mm diameter and 10 mm length (American Orthodontics, Sheboygan, WI, USA), uncoated and non-irradiated. Patients will use 0.2% chlorhexidine mouthwash (Nazhou, Iran), twice daily for 30 seconds according to manufacturer’s instructions.</i_keyword>
      <i_keyword>Intervention group 5 (Negative control): Titanium miniscrew, 1.6 mm diameter and 10 mm length (American Orthodontics, Sheboygan, WI, USA), uncoated and non-irradiated, without any adjunctive treatment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Stability. Timepoint: Immediately after placing the mini-screw and on days 7, 14, and 30 after placement. Method of measurement: Osstell ISQ RFA device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Concentration of inflammatory factors (TNF-α and IL-1β). Timepoint: Immediately after mini-screw placement and on days 7, 14, and 30. Method of measurement: ELISA Kit.</sec_outcome>
      <sec_outcome>Gingival index score. Timepoint: Immediately after placing the mini-screw and on days 7, 14, and 30 after placement. Method of measurement: Modified Gingival Index based on Löe &amp; Silness.</sec_outcome>
      <sec_outcome>Pain. Timepoint: Immediately after placing the mini-screw and on 7th after placement. Method of measurement: Visual Analogue Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-07-21</approval_date>
        <contact_name>Research Ethics Committees of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences (IUMS), Shahid Hemmat Highway, Tehran, IRAN Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
